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Parasitic nematodes manufacture various carbohydrate-
linked phosphorylcholine (PCh)-containing molecules, includ-
ing ES-62, a protein with an N-linked glycan terminally substi-
tuted with PCh. The PCh component is biologically important
because it is required for immunomodulatory effects. We
showed that most ES-62 was bound to a single protein, C-reac-
tive protein (CRP), in normal human serum, displaying a cal-
cium-dependent, high-avidity interaction and ability to form
large complexes. Unexpectedly, CRP binding to ES-62 failed to
efficiently activate complement as far as the C3 convertase stage
in comparison with PCh-BSA and PCh-containing Streptococ-
cus pneumoniae cell wall polysaccharide. C1q capture assays
demonstrated an ES-62-CRP-C1q interaction in serum. The
three ligands all activated C1 and generated C4b to similar
extents. However, a C2a active site was not generated following
ES-62 binding to CRP, demonstrating that C2 cleavage was far
less efficient forES-62-containing complexes.Weproposed that
failure of C2 cleavage was due to the flexible nature of carbohy-
drate-boundPCh and that reduced proximity of theC1 complex
was the reason that C2 was poorly cleaved. This was confirmed
using synthetic analogues that were similar to ES-62 only in
respect of having a flexible PCh. Furthermore, ES-62 was shown
to deplete early complement components, such as the rate-lim-
iting C4, following CRP interaction and thereby inhibit classical
pathway activation. Thus, flexible PCh-glycan represents a
novel mechanism for subversion of complement activation.
These data illustrate the importance of the rate-limiting C4/C2
stage of complement activation and reveal a new addition to the
repertoire of ES-62 immunomodulatory mechanisms with pos-
sible therapeutic applications.
Phosphorylcholine (PCh)4 is linked to a variety of structures
in a range of microorganisms. Filarial nematode products are
particularly heavily substituted with PCh and include a number
of somatic and excreted antigens of medically important
human parasites, such as Brugia malayi (and also the feline
parasite Brugia pahangi) (1, 2), Onchocerca volvulus (3), and
Wuchereria bancrofti (4). Most studied of the PCh-containing
molecules is ES-62, a major secreted product of the adult stage
of the rodent filarial nematode Acanthocheilonema viteae,
which acts as a model for human filarial nematode PCh-con-
taining proteins. This tetrameric glycoprotein has PCh at-
tached viaN-glycan terminal linkage, and each ES-62 molecule
can have at least two PCh per glycan (5, 6). ES-62 has a broad
immunomodulatory activity, such as the ability to inhibit lym-
phocyte responses andmacrophage activation (7, 8), and PCh is
required for this activity (7, 9). Themolecule is currently under
study for its therapeutic potential because it has been shown to
reduce inflammation in a number of models of inflammatory
disease; for example, collagen-induced arthritis, which acts as a
model for rheumatoid arthritis (10, 11).
We were therefore interested in examining which host pro-
teins would interact immediately with ES-62 following its
secretion and appearance in the bloodstream. This is a question
that is of relevance to human filariasis because PCh-containing
antigens are known to appear in the serumof filarial nematode-
infected individuals (12). One candidate was C-reactive protein
(CRP) because this protein binds to PCh on bacteria, including
Streptococcus pneumoniae, which incorporates PCh into its cell
wall polysaccharide (CWPS) (13). However, in contrast to the
well characterized binding of CRP to bacteria, binding to para-
sites and parasite ligands is poorly studied. Additionally, it is of
interest that the PCh on ES-62 is in a phosphodiester linkage,
and such compounds have been reported to have a 10-fold
reduced binding capacity for CRP compared with monoesters
(14). For S. pneumoniae, the binding of CRP is detrimental
because it can potentially lead to killing of the bacteria by com-
plement activation (15), and endogenous mouse CRP defi-
ciency can lead to a great increase in susceptibility (16). In con-
trast however, and as alluded to above, PCh structures present
on or secreted by awide range of nematodes and other parasites
can have beneficial roles for the parasites, in particular for eva-
sion of the immune response (17, 18). CRP is known as an
important component of the innate immune response and a
clinical marker of systemic inflammation because of its dra-
matic rise following infection, trauma, or other pathology,
when it may increase in concentration by at least 1000-fold
from a baseline concentration, which is often less than 1g/ml.
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This induction is driven within 24–48 h by a variety of inflam-
matory cytokines, but interleukin 6 is essential, and interleukin
1 greatly enhances responses (19).
CRP is composed of a pentameric ring of subunits of25 kD
arranged in the same plane, with each subunit in the same ori-
entation (20). When CRP binds to PCh or other ligands, it has
been shown to activate complement throughC1q binding as for
the classical pathway. The central pore and cleft on the other
side of the pentamer from the ligand-binding site is involved in
binding to the globular headgroup of C1q (21, 22). Binding of
CRP to factor H and C4 binding protein is not observed at
normal concentrations of the native form or ligand-boundCRP
(23–26). Therefore, the second aimof this studywas to examine
the activation of complement by ES-62 because this appeared
counterintuitive for the filarial parasite and, in particular, for a
molecule that has immunomodulatory and anti-inflammatory
activity. Activation of complement and, in particular, C3 cleav-
age is important not just for innate immunity but also for driv-
ing T cell responses (27) and for humoral immunity (28). We
demonstrate that, despite strong binding for CRP, ES-62 did
not generate a C3 convertase because of the unusual presenta-
tion of a CRP ligand at the end of a highly extended and flexible
30-Å glycan structure. This is very different in terms of spatial
rigidity to PCh directly coupled to BSA or found in bacterial
carbohydrates such as C polysaccharide and thereby consti-
tutes a novel immune evasion strategy. This was confirmed by
demonstrating that the same properties are displayed by syn-
thetic analogues that resemble ES-62 only in possessing mobile
PCh.
Experimental Procedures
Materials
Serumwas obtained from normal healthy donors at the Lon-
don School of Hygiene and Tropical Medicine under informed
consent and ethical approval and assayed for CRP by ELISA.
Highly purified, endotoxin-free ES-62 was generated from cul-
ture supernatants of adultA. viteae as described previously (29).
Purified CWPS was obtained from the Statens Serum Institute
(Copenhagen, Denmark). PCh-BSAwas generated as described
previously (28). Native CRP and SAP were purified from serum
as described previously (30, 31). Mouse myeloma protein,
TEPC-15, which recognizes PCh, was obtained from Sigma.
Mouse monoclonal antibody 2C10 to native human CRP was
provided by Dr. L. Potempa. C1q-deficient serum was supplied
by Quidel. Antibody to the active site of C2a (175–62) was
provided by Genentech.
ES-62 and Serum Protein Binding Assays
Pentraxin Binding Assays—Nunc Maxisorb plates were
coated with ES-62, PCh-BSA, or CWPS at the stated concen-
trations in PBS (pH 7.4) overnight at 4 °C. Blocking was per-
formed with 1% w/v BSA in PBS containing 0.05% v/v Tween
20. Purified CRP or human serum diluted as stated in HEPES-
buffered saline containing 1mMCaCl2 and 0.05% v/v Tween 20
(HBSCT) was added to wells for 1 h at 20 °C. In some experi-
ments, 10 mM EDTA or 50 mM phosphorylcholine was added.
The plate was washed in HBSCT, and bound CRP was detected
with polyclonal anti-CRP-HRP conjugate (Dako), followed by
washing and 1,1,3,3 tetramethylbenzidine substrate (0.1
mg/ml, Fisher) in 50mM citrate-phosphate buffer (pH 4.5) con-
taining 0.005% H2O2) detection at 450 nm. Alternatively, CRP
was detected with monoclonal anti-human CRP (2C10) recog-
nizing native CRP. After washing, this was detected with anti-
mouse IgG-HRP (Sigma). To analyze serum amyloid P (SAP)
binding, we used the same detection protocol but replaced anti-
CRP with monoclonal anti-SAP (5.4A, Millipore).
Ficolin-2 Binding Assay—NuncMaxisorb plates were coated
with ES-62 or acetylated BSA (Sigma) ligands at the indicated
concentrations. These were then each blocked with 10 mM
HEPES-buffered saline with 1mMCaCl2 (HBSC) containing 2%
(w/v) BSA and washed in HBSCT. Human serum was diluted
1/20 with either HBSCT or HBST (HEPES-buffered saline con-
taining 0.05% (v/v) Tween 20) containing 5mMEDTA and then
incubated on the plate for 1 h at room temperature. Following
further washes in the appropriate buffer, biotinylated anti-fico-
lin 2 (R&D Systems), diluted 1/200, was added to each well, and
the plates were incubated for 1 h at room temperature. Binding
was detected with streptavidin-peroxidase (BIOSOURCE (1/
15,000) and 1,1,3,3 tetramethylbenzidine substrate as de-
scribed previously.
Serum Pulldown Assays
100 l of amine-coated magnetic beads (10 mg/ml, 1-m
diameter, MoBiTec) was incubated with 5 l of 10 mg/ml fresh
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in 0.1 MMES
buffer (pH 4.5) with 25 l of 250 g/ml ES-62 or 1 mg/ml
AGP-PCh in the same buffer. Beadswere incubatedwith rolling
at room temperature overnight before being washed with PBS
and a magnetic activated cell-sorting magnet. Beads were
blocked with BSA and incubated with serum, 1 ml from pooled
normal donors, for 2 h at room temperature with rolling,
washed five times with 10mMHEPES (pH 7.4) containing 1mM
CaCl2, and then eluted with 50 l of 10 mM EDTA in HEPES
buffer or directly into sample buffer. The supernatant and
beads were boiled in SDS sample buffer before SDS-PAGE
(11%) gel analysis using Coomassie Blue or Western blotting.
Surface Plasmon Resonance
ABiacore 3000 was used to immobilize 300 response units of
ES-62 on a CM5 chip (Biacore, Stevenage, UK). To achieve this,
ES-62 (20 g/ml in 10 mM sodium acetate buffer (pH 5.5)) was
coupled via standard amine coupling. Test and control flow
cells were blocked with ethanolamine, and the binding experi-
ments were performed in HBS containing 1 mM CaCl2 and
0.005% surfactant P20 (pH 7.4). Various concentrations of CRP
(10 g/ml-20 ng/ml) were passed through the flow cells at 10
l/min for 3 min and allowed to dissociate for a further 5 min.
Binding of ES-62 to immobilized CRP was examined by ini-
tially attaching streptavidin (in 10 mM acetate buffer (pH 5.5))
to 5000 response units to flow cells 1–4 of a CM5 chip using
amine coupling and ethanolamine deactivation. Biotinylated
CRP and SAP were generated by reaction with NHS-LC-biotin
(Cayman Biochemicals) in PBS (pH 7.4), and unreacted biotin
was removed by dialysis. Biotinylated protein was repurified
using phosphoryl-ethanolamine or PCh affinity chromatogra-
phy. CRP-biotin and SAP-biotin diluted in HBS containing 3
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mM EDTA and 0.005% surfactant P20 were attached to the
streptavidin to 200 response units. A third empty flow cell was
used as a control. Between samples of ES-62 (3-min association,
5-min dissociation, 30l/min) diluted inHBS (pH7.4) contain-
ing 1 mM CaCl2 and 0.005% (v/v) surfactant P20, complete
regeneration of flow cells was achieved with HBS containing 3
mM EDTA. Data analysis used BIAevaluation software (version
4.1.1) by separate calculation of ka and kd.
SDS-PAGE and Ligand Blotting
ES-62 was subjected to SDS-PAGE on 12% gels, and the gels
were either stained with Coomassie Blue or transferred to
PVDFmembranes. Molecular weight standards were Precision
Plus Kaleidoscope (Bio-Rad). Membranes were blocked with
1% (w/v) BSA in PBS containing 0.05% v/v Tween 20 and 0.5
mM CaCl2 (PBSTC). Membranes were then incubated with 10
g/ml CRP or TEPC15 (1 in 1000) in PBSTC or PBST contain-
ing 5mMEDTA for 1 h at room temperature. CRPwas detected
with monoclonal anti-CRP (2C10) followed by anti-mouse
IgG-AP conjugate (Sigma). Anti-PCh IgA binding (TEPC15)
was detectedwith anti-mouse Ig-AP (Sigma). The chromogenic
substrate was 5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium (BCIP/NBT) (in sodium carbonate buffer (pH
9.6) plus 2 mM MgCl2). Quantitation of the relative density of
protein staining in gels was performed using ImageJ.
Analysis of Complexes
The size of complexes was determined by dynamic and static
light scattering (Malvern Instruments,  NanoS). The samples
were diluted to a final concentration of 50 g/ml in 10 mM
HEPES (pH 7.4) containing 0.15 M NaCl with no further addi-
tions or with 1 mM CaCl2 or 5 mM EDTA. Analysis was per-
formed for five cycles. The standards used to confirm size were
ovalbumin and thyroglobulin. HPLC was performed with a
G4000SW column (300 10mm) calibrated with the gel filtra-
tion markers blue dextran (Vo), thyroglobulin, albumin,
ovalbumin, and glycyl tyrosine (Vt). Samples of ES-62 were run
in a column equilibrated in HBSC buffer with or without CRP
incorporated at 20 g/ml or with EDTA to inhibit the
interaction.
Complement Assays
C1q Capture Assay—An adaptation of an immune complex
capture assay was used to detect complexes formed between
CRP and ES-62 in serum. Purified C1q (Calbiochem) was coated
onto Immulon 4HB plates at 10 g/ml overnight at 4 °C. Plates
were then incubated with 3% (w/v) BSA in PBST for 2 h. Serum
was diluted at 1:5; 1:10 or higher dilutions with or without
added CRP in veronal-buffered saline (VBS) with 0.15 mM
CaCl2 and 0.5 mM MgCl2 containing 0.2% w/v gelatin (GVB-
SCaMg) and ES-62 added at 1 g/ml; 0.5 g/ml, 0.1 g/ml, or
no ligand was added. The plate was incubated at room temper-
ature for 1 h and then washed, and bound CRP was detected
with anti-CRP. Bound protein was also analyzed by 12% SDS-
PAGE and Western blotting for C1q and CRP on PVDF.
C1q Binding Assay—NuncMaxisorb plates were coated with
PCh-BSA, CWPS, or ES-62 at various concentrations (5.0–0.1
g/ml) to allow equivalent binding of C-reactive protein as
determined by anti-CRP as above. Plates were washed with
HBSTC and blocked with the same buffer containing 1% (w/v)
BSA. CRP was added at various concentrations for 1 h at room
temperature, followed by various concentrations of humanC1q
(Calbiochem) for 1 h at room temperature and goat anti-C1q
(Calbiochem). Bindingwas detectedwith anti-goat IgG alkaline
phosphatase (Sigma) and 1 mg/ml p-nitrophenyl phosphate in
bicarbonate buffer (pH 9.6) containing 2 mM MgCl2.
C3 and C4 Deposition Assays—To assess C3 deposition,
ligand was coated to wells at various concentrations (ES-62,
0.25–0.05 g/ml; CWPS, 2.5–0.5 g/ml; PCh-BSA, 0.05–0.25
g/ml). Human fresh serum obtained from volunteers was
added to the wells at 1/100 dilution in GVBSCaMg, GVB-
SMgEGTA (0.5 mM MgCL2 and 5 mM EGTA), or GVBSEDTA
(5mM EDTA). CRP (0.4g/ml) or no addition wasmade to test
or control wells. Plates were incubated at 37 °C for 30 min and
washed with HBSTC. C3d deposition was detected with sheep
anti-humanC3d diluted 1/10,000 (Binding Site) and anti-sheep
IgG alkaline phosphatase conjugate. Sera depleted of CRP were
generated using adsorption with PCh-Sepharose 4B. All other
sera used had endogenous CRP of less than 10 ng/ml final con-
centration prior to CRP addition. For iC3b, deposition plates
were washed, and iC3b was detected with 1 g/ml biotinylated
antibody to the neoepitope of iC3b (Quidel), followed by
streptavidin-HRP (Invitrogen). C4 deposition was measured
with biotinylated polyclonal antibody to C4c, which also recog-
nizes C4b (Dako) in combination with streptavidin HRP.
C2 Cleavage Assay—To determine the amount of C2a gen-
erated and bound to C4b at the plate surface, an antibody
(175-62) that recognizes the active site of C3 convertase gen-
erated after C2 cleavage was used. This antibody was pro-
vided by Genentech and biotinylated using NHS-LC-biotin
(Cayman Chemicals) via the protocol of the manufacturer.
Plateswere coatedwith ligand, and 50l of serumdiluted 1/100
in GVBSMgCa, GVBSMgEDTA, or GVBSEDTA and biotiny-
lated anti-C2a (0.7g/ml) with or without CRP (0.4g/ml) was
added to replicate wells. The plates were then heated to 37 °C
for 20 min, washed with PBST, and incubated with streptavi-
din-HRP (BIOSOURCE, 1/15,000).
C4-binding Protein (C4bp) Binding Assay—To assess C4
binding protein deposition, Maxisorb plates (Nunc) were
coated with ligand as for the C4 binding assay and blocked with
PBS containing 0.2% w/v gelatin (Sigma). Serum was diluted 1
in 100 inGVBSCaMgorGVBSMgEGTAwith orwithout added
CRP, and the plates were incubated at 37 °C for 30 min. The
plates were washed, and C4 binding protein deposition was
measured with biotinylated polyclonal antibody to C4bp (Sero-
tec) diluted 1:1500. After washing, streptavidin-alkaline phos-
phatase (Serotec) was used at 1:3000 with p-nitrophenyl phos-
phate as substrate.
Factor H Binding Assay—Maxisorb plates (Nunc) were
coated with ligand as above and blocked with PBS containing
0.5% w/v gelatin (Sigma). Serum was diluted 1 in 100 in
GVBSCaMg or GVBSMgEGTA with or without added CRP,
and the plates were incubated at 37 °C for 30 min. After wash-
ing, bound Factor H was measured using a biotinylated anti-
human factor H. This reagent was generated from goat poly-
clonal antibody to factor H (Calbiochem) biotinylated with
Ligand-dependent CRP-mediated Complement Activation
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NHS-LC-biotin (Cayman). Detection with streptavidin-HRP
was performed as described previously.
IgM-induced Classical Pathway Assay—Immulon 4 HBX
plates were coated with 50 l of human IgM (Sigma) at 1.6
g/ml in 0.1 M carbonate buffer (pH 9.6) overnight at 4 °C.
Wells were blockedwith PBS containing 1%BSA (w/v) for 2 h at
room temperature. Serum was diluted 1/100 in GVBSCaMg or
GVBSMgEGTA, added to plates, and incubated for 30 min at
37 °C. IgM-activated C3d deposition was detected as described
for C3 activation. To examine the effects on classical pathway
activity, ES-62 was added at 0.1 g/ml with or without CRP for
30 min at 37 °C prior to addition to the IgM-coated plates.
Active C4 Depletion Assay—This assay is based on the dem-
onstration that the active thioester of C3, C4 (and 2-macro-
globulin), can be reacted with a hydrazide and that only active
protein will generate a stable labeled biotin derivative (32). This
is captured by anti-C4, and the amount of derived C4 is deter-
mined using streptavidin-HRP. Serum was diluted 1/100 in
GVBSCaMg or GVBSMgEGTA in the presence or absence of
added CRP at 0.4g/ml. Individual microcentrifuge tubes con-
taining 20 l of diluted serumwere supplemented with control
buffer or ES-62 (0.5 g/ml) or other concentration or ligand
and incubated at 37 °C for 1 h. 2 M NaCl (20 l) was added to
each tube together with 2 l of 10 mM biotin-PEG4-hydrazide
(Thermo Scientific) in DMSO. The tubes were then heated to
52 °C for 1 h and cooled. The reaction mixture was left over-
night in the fridge before the assay.
NuncMaxisorb plateswere coatedwith affinity-purified goat
anti-C4 (0.2 g/ml, Immune Consultant Laboratories), and
plates were blocked with PBST containing 2% (w/v) BSA.
Samples treated as above were diluted to the point at which
they gave a linear response in the assay (1–800) and incu-
bated at room temperature for 2 h. A standard curve on each
plate was generated from a treated C4 standard. Bound bio-
tin-labeled C4 was determined using streptavidin-HRP con-
jugate (BIOSOURCE).
Synthesis of AGP-PCh
AGP was purified from human serum using anion exchange
chromatography (DE52), Cibacron-Blue-Sepharose, and then
another anion exchange stage to purify AGP1 (modified from
Ref. 33). It was dialyzed into 0.1 M phosphate buffer (pH 7.4)
containing 0.15MNaCl and then oxidized to targetmainly sialic
acidwith 2.5mM sodiumperiodate for 1 h at room temperature.
The protein was desalted on a PD-10 column (GE Healthcare)
into 0.1 M phosphate buffer, and p-aminophenyl-PCh was
added at 1 mM final concentration (50 molar excess), fol-
lowed by sodium cyanoborohydride to give a final concentra-
tion of 50 mM. After incubation in the dark overnight at 4 °C,
the protein was again desalted on a PD-10 column.
Deglycosylation of AGP-PCh and ES-62
PNGase F (Promega) was used to remove the N-linked car-
bohydrate according to the protocol of the manufacturer. 12.5
g of AGP-PCh or 10 g of ES-62 was denatured and digested
with 2 units of PNGase in phosphate buffer for 3 h at 37 °C. The
removal of PCh was confirmed by Western blotting using the
anti-PCh myeloma protein TEPC15 and anti-mouse immuno-
globulin-alkaline phosphatase and detection with 5-bromo-4-
chloro-3-indolyl phosphate/nitro blue tetrazolium substrate.
Synthesis of BSA-PEG4-PCh
10 mM propargyl-NHS (Sigma) in DMSO (600 l) was incu-
batedwith 10mg/mlBSA (3ml) in PBS at room temperature for
2 h. The BSA-alkyne generatedwas desalted on a PD10 column.
2mg p-aminophenyl-phosphorylcholine was dissolved in 1.0
ml 0.1MMES (pH4.5) and added to an equal volumeof 1mg/ml
azide-PEG4-COOH (Iris Biotech) and 0.2ml 10mg/ml 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide and incubated over-
night at room temperature. The azide-PEG4-phenyl-PCh was
separated from the smaller precursors on a Biogel P2 column
(15 ml, Bio-Rad) washed with PBS. Click chemistry between
azide and alkyne was used to generate the BSA-PEG4-PCh con-
jugate. The reaction was composed of 1.0 ml of 0.2 mM BSA-
alkyne and 0.7 ml of 0.3 mM azido-PEG4-phenyl-PCh, 2 l of
500 mM fresh ascorbic acid, 50 l of copper/Tris-[(1-benzyl-
1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) reagent (1 volume
of 10 mM copper II/2 volumes of 50 mMTBTA, Sigma), and the
reagents were incubated for 2 h with rolling. The BSA-PEG4-
PCh-containing fractions were collected after desalting on a
PD10 column.
Results
CRP Binds to ES-62 with High Avidity—We immobilized
ES-62 on a microtiter plate and examined its ability to bind
purified CRP in comparison with the known natural ligand
CWPS and a synthetic ligand, PCh-BSA. CRP showed concen-
tration-dependent binding to ES-62 with a similar concentra-
tion required for half-maximal binding to each of the three
ligands (Fig. 1A). Coating the plate with concentrations of
ES-62 as low as 10–20 ng/ml, we were able to detect binding of
CRP from serum (Fig. 1B). This binding of CRP was detectable
with a monoclonal antibody to native CRP and could be inhib-
ited with EDTA or PCh, thereby confirming that the binding
was calcium-dependent and through the PCh-binding site of
CRP. Although no SAP could be seen binding to PCh-BSA, the
interaction of SAP could only be observed at the highest con-
centrations of immobilized ES-62 (Fig. 1C). Little or no IgM
binding was detected, probably because IgM specific for PCh is
reported at low concentrations in human serum. Despite the
reported high amount of terminal N-acetylglucosamine in
ES-62 (5), ficolin-2 was not bound (Fig. 1D). ES-62 was then
subjected to SDS-PAGE, and, following transfer to a mem-
brane, we used ligand blotting with CRP and anti-CRP to dem-
onstrate that theCRPbounddirectly to the ES-62 (Fig. 1E). CRP
binding required the presence of the PCh on the N-linked car-
bohydrate because PNGase F digestion abrogated CRP (and
anti-PCh) binding (Fig. 1E)). Initial plate experiments (Fig. 1,
A–C) suggested a high avidity of binding. To confirm this, we
used surface plasmon resonance with immobilized ES-62 and
demonstrated a major high avidity component with a Kd of
1  1010 M, although complex binding kinetics are to be
expected in pentameric and multimeric ligand interactions
because some analyte will bind at more than one site (Fig. 1F).
Off-rates varied between 0.6–1.4  103 s1 at different con-
centrations, but on-rates were very fast: 3 106-107 M1s1. In
Ligand-dependent CRP-mediated Complement Activation
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the reverse orientation (ligand and analyte exchangedwith each
other), we employed a gentle way to label CRP with biotin at
neutral pH and captured this on a surface of immobilized
streptavidin. The off-rate (Kd) was highly reproducible in the
range of 1.4–1.3  103 s1 over the range of concentrations
tested, but the on-rate fit was less consistent, between 1 105
and 1  106 M1s1. The Kd in this orientation was slightly
lower, between 0.8 and 3 109 (Fig. 1G). SAP immobilized in
this orientation failed to bind to ES-62.
Purified ES-62 and CRP Can Form Large Complexes in Fluid
Phase—It was of interest to discover whether the interaction
between CRP and ES-62 was capable of generating complexes
in fluid phase. In preliminary experiments, we analyzed ES-62
alone in buffer containing 1 mM CaCl2 using a gel filtration
column that eluted at the appropriate molecular weight (240
kD), running as a tetramer as reported previously. When CRP
was incorporated into the buffer of this gel filtration system and
ES-62 was injected, no peak of ES-62 was observed. Rather, a
depletion of CRP was observed, consistent with formation of a
complex too large to enter the column. When the same exper-
iment was repeated in the presence of EDTA or in calcium
without CRP, ES-62 was observed at its expected molecular
weight. To confirm the interaction, we used non-invasive light
backscattering to show that adding ES-62 with an equimolar
concentration of CRP led to all CRP and ES-62 forming a large
complex 0.1–2 m in diameter (Fig. 1H).
CRP Is the Major ES-62-binding Protein in Serum—CRP
binding to ES-62was similar whether or not serumwas present,
suggesting that there was little or no competing protein in
serum and, therefore, CRP was the major ES-62-binding pro-
tein (Fig. 2A). To further confirm this, we initially used ES-62-
Sepharose 4B to examine the binding of serum proteins and
detected the major specific bands eluted as CRP and SAP (data
not shown). SAP is known to bind minor components of aga-
rose, and given potential for cross-reactionwith the support, we
then coupled ES-62 to an amine-coated magnetic silica bead
support and re-examined proteins pulled out of serum. This
confirmed that CRP was the major protein bound from serum
(Fig. 2B), comprising 80–85% of eluted protein by gel densi-
tometry, whether this was calcium-dependent (EDTA elution)
or not (SDS lysis buffer elution). On this support, only trace
amounts of SAP were bound.
FIGURE 1.High-avidity bindingof C-reactive protein to ES-62 is calcium-dependent and canbe inhibitedbyPCh.A, dose response of binding of purified
CRP to immobilized ES-62 (2.0g/ml, f), PCh-BSA (0.5g/ml, Œ), or CWPS (5g/ml,) onmicrotiter plates. Various concentrations of CRP were offered, and
binding of CRPwas detected using polyclonal anti-humanCRP-HRP.OD, optical density. B, CRP binding fromES-62 is calcium-dependent and can be inhibited
by PCh. Various concentrations of ES-62were coated ontomicrotiter plates, and normal serum diluted 1 in 50 to give a final CRP concentration of 50 ng/ml
was added. Binding of CRP was detected with the anti-native human CRP monoclonal antibody 2C10 and anti-mouse IgG HRP and 1,1,3,3 tetrameth-
ylbenzidine substrate (optical density, 450 nm). Serum was diluted in HBS containing 1 mM CaCl2 (Œ), HBS with 10 mM EDTA (‚), or HBS with 1 mM CaCl2
and 50 mM phosphorylcholine (). C, SAP provided in serum diluted 1 in 50 binds weakly to ES-62 (Œ) but not PCh-BSA-coated plates (f). SAP was
determined usingmonoclonal anti-SAP and anti-mouse IgGHRP. Controls show binding to ES-62 in the presence of EDTA (‚).D, plates were coatedwith
ES-62 or the positive control acetylated BSA (ACBSA) at various concentrations, serumwas added in the presence or absence of calcium, and bindingwas
detected with biotinylated anti-ficolin 2 and streptavidin HRP. Data are mean  S.E. of triplicates. E, ligand blotting of ES-62 following SDS-PAGE
demonstrates binding of C-reactive protein to PCh attached to N-linked glycan. Left panel, ES-62 or ES-62 deglycosylated with PNGase stained directly
with Coomassie Blue (CB). Center panel, ES-62 was transferred to PVDF, and CRP binding in TBSC was detected with anti-CRP and anti-mouse-alkaline
phosphatase. Right panel, as for the center panel, but PCh was detected with anti-PCh myeloma protein, TEPC15. WB, Western blotting. F, surface
plasmon resonance analysis of interaction. ES-62 was immobilized, and CRP was offered at concentrations of 10, 2.5, 1.25, 0.62, 0.3, 0.16, 0.08, and 0.04
g/ml. Langmuir 1:1 analysis was performed. Residuals from the association analysis are shown below. RU, response unit. G, surface plasmon resonance
analysis of ES-62 (12.5, 6.25, 3, 1.6, 0.8, 0.4, and 0.2 g/ml) binding to biotinylated CRP immobilized on a streptavidin surface. The superimposed lines
show modeled fit. H, CRP and ES-62 form large complexes in fluid phase. The size of the complex was determined using light scattering 5 min after
mixing for 50 g/ml CRP and 65 g/ml ES-62 in HBS in the presence of 1 mM CaCl2.
FIGURE 2.CRP is themajor serumprotein binding to ES-62. A, other serum
proteins do not inhibit CRP binding to ES-62. ES-62 (0.25 g/ml) was coated
ontomicrotiter plates, and CRP at indicated concentrations was added alone
() or in thepresenceof two individual normal serumsamples (f andŒ). CRP
binding was detected as for Fig. 1B. OD, optical density. B, CRP is the major
protein pulled out of normal serumby ES-62 (lanes 1 and 2) or AGP-PCh (lanes
3 and 4) coupled to magnetic beads. Bound protein was eluted with EDTA
(lanes 1 and 3) or by SDS-PAGE lysis buffer (lanes 2 and 4). SDS-PAGEgelswere
run and analyzed by Coomassie Blue staining (lanes 1–4). Gels were also
immunoblotted, and CRP eluted from ES-62-coated beads was detected by
Western blotting (lane 5), as was SAP to a lesser degree (lane 6).
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CRP Bound to ES-62 Does Not Generate C3 Degradation
Products—The PCh ligand of CRP in ES-62 is present on the
end of a long and flexible carbohydrate chain, and it was uncer-
tain how this might affect the ability of CRP to activate comple-
ment. Pooled or individual normal donor sera with a CRP con-
centration of less than 1 g/ml were diluted to give a final CRP
of less than 10 ng/ml, and native CRP was added at 400 ng/ml.
Complement activation was assessed using ligand-coating con-
centrations chosen to lead to equivalent CRP bound. CRP
increased C3d deposition onto the PCh-containing ligands
PCh-BSA and CWPS, but no increase was seen with ES-62 (Fig.
3A). We assayed the amount of CRP bound in these interac-
tions, and to rule out effects because of different CRP binding,
we repeated the experiment with a range of CRP concentra-
tions. However, even at the higher amounts of CRP bound to
ES-62, little or no additional C3d was deposited in comparison
with the other ligands (Fig. 3B). Because CRP has been reported
to activate complement through factor H-like proteins (32) and
lectin pathway activation may be a contributor to C3 deposi-
tion, we determined whether the activation was C1q-depen-
dent using C1q-deficient sera. Activation was reduced to back-
ground in the absence of C1q (Fig. 3C), showing that CRP
worked exclusively through C1q and that the classical/
CRP-mediated pathway was predominant in CRP-mediated in-
creases in C3d deposition. We also checked for formation of
another C3 cleavage product, C3bi, which againwas induced by
PCh-BSA but not ES-62 (Fig. 3D).
CRP Bound to ES-62 Recruits C1 and Cleaves C4—We
wanted to determine atwhat stageCRPbound toES-62 failed to
activate complement. Therefore, we tested the ability of puri-
fied C1q to bind to CRP when bound to CWPS, PCh-BSA, or
ES-62. Immobilized ES-62 with bound CRP was as efficient at
binding purified C1q as other ligands (Fig. 4A). To determine
whether the interaction took place in whole sera, plates were
coated with C1q and ES-62 or other ligand added to sera, and
CRP-ligand complex bindingwas determined. C1q did not cap-
ture CRP in the absence of ligand, but when any of the three
ligandswas added to the sera, thenCRP could be detected bind-
ing to C1q (Fig. 4B). The maximal binding was observed at an
approximate equivalence of molar amounts of CRP and ES-62
(Fig. 4C). Such plates were washed, and bound material was
analyzed byWestern blotting, and the binding of CRP and C1q
was shown to be calcium-dependent (Fig. 4D).
We then employed an assay of C4 deposition, which was
similar to that for C3d deposition. ES-62 and the other positive
control ligands all resulted in CRP complexed with C1 and
cleaved C4 (Fig. 5A). There was a correlation between the
amount of bound CRP and the deposition of C4 (Fig. 5B; linear
correlationwas significant at p 0.02, 0.01, and 0.03 forCWPS,
ES-62, and PCh-BSA, respectively).
Failure of the ES-62CRP Complex to Lead to Activated C3
Convertase Does Not Lie with Recruitment of C4-binding Pro-
tein or Factor H—Complement control proteins have been
reported to interact with CRP. However, no increase in C4bp
recruitment to ES-62-CRP was observed. C4bp was not
involved in the failure of ES-62CRPC1q to result in an acti-
vated C3 convertase (Fig. 6A). The amount of factor H recruit-
ment to PCh-BSA- and CWPS-coated plates during incubation
was increased by the presence of CRP in serum, but this was not
seenwith ES-62 (Fig. 6B). This was consistent with the idea that
C3 convertase was not generated downstream of CRP binding
to ES-62.
Failure of the ES-62CRP Complex to Result in Activated C3
Convertase Lies with the Inability to Cleave C2—The mecha-
nism of C3 convertase formation requires that C2 binds to C4b
generated close to the C1 complex and that the C1s cleaves the
C2 before the C4b is inactivated. Using a complement activa-
tion assay based on amonoclonal antibody that recognizes only
active C2a, we observed an increase in C2a formationmediated
downstream of CRP binding to PCh-BSA but not ES-62 (Fig. 7).
Therefore, although equivalent C4b is generated in response to
the ES-62CRPC1 complex, the efficiency of cleavage of
recruited C2 is greatly reduced.
High Flexibility of Phosphorylcholine-containing Ligands
Leads to Failure of Bound CRP to Activate Complement—This
failure to induce C3 convertase formation was related to the
lack of C2 cleavage despite equivalent C4 activation.We postu-
lated that this was due to the flexibility of the ligand for CRP
and, consequently, the boundCRP and bound complex. TheC1
complexwith activeC1swould cleave theC4 thatwould bind to
a reactive site near the complex, but when C2 subsequently
interacts with the C4, the enzyme is no longer close enough to
efficiently cleave the C2 to generate C4bC2a (C3 convertase).
To investigate this, we considered that a PCh ligand placed on
any similarly sized glycan chain would share this property. To
generate an analogue, we used 1-acid glycoprotein (AGP),
which has fourN-glycans largely terminating in sialic acid, and
added PCh through reductive amination. This ligand also
pulled out only CRP from human serum (Fig. 2B). For analysis
of complement activation, the PCh ligand density was adjusted
to give similar levels of CRP binding to the plate. This synthetic
version of the glycan with terminal PCh also failed to activate
C3, as shown by no additional C3d deposition on CRP addition
(Fig. 8A). The PCh on this AGP was carbohydrate-linked
because PCh was not detected after treatment with PNGase F,
as shown by SDS-PAGE and Western blotting (Fig. 8C).
Because this ligand is also carbohydrate-bound, we gener-
ated a further synthetic version with a highly flexible PCh using
a PEG spacer that had an approximately similar length as ES-62
carbohydrate (35). This was generated by initial carbodiimide
coupling of p-aminophenyl PCh and azide-PEG4-COOH to
produce azide-PEG4-phenyl-PCh and then click chemistry to
couple this to an alkyne derivative of BSA. CRP bound to this
ligand generatedno additionalC3ddeposition. Thiswas in con-
trast to when comparable amounts of CRPwere bound to BSA-
PCh ligand lacking the spacer but that was otherwise identical,
thus indicating again that the feature of the PCh that was
important was its presence on a terminal flexible spacer (Fig.
8B). The comparable binding of CRP to these ligands was also
reflected in the analogous cleavage and deposition of C4 follow-
ing CRP binding to AGP-PCh and BSA-PEG-PCh (Fig. 8D), as
demonstrated previously for ES-62.
The ES-62CRP Complex Depletes Classical Pathway Activa-
tion and the Rate-limiting Component C4—Flexible ligand had
initiated C4 cleavage, as summarized in Fig. 9A, but failed to
activate C3 convertase. To assess whether ligand such as ES-62
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present in serumduring infection andCRPwould alter comple-
ment activity, we added the nematode product to serum and
then examined the ability of that serum to be activated by an
IgM-driven classical complement pathway assay.Wemeasured
C3d deposition following activation with surface-immobilized
IgM. When ES-62 was added at a concentration of 0.1 g/ml
(enough to complex all available CRP in the diluted serum),
there was a consistent and statistically significant reduction in
the capacity of the sera to deposit C3d (Fig. 9B). It has been
determined previously that the concentrations ofC2 andC4 are
FIGURE 3. ES-62, in contrast to PChBSA and CWPS, does not lead to C3d or C3bi deposition. A, CRP increases deposition of C3d onto PCh in PChBSA and
CWPS but not ES-62. Individual sera fromhealthy donors with or without added CRP in VBSCaMgwere incubated at 37 °C in ligand-coated plates in VBSCaMg,
and C3d deposition was determined. The background level of complement activation for ES-62 seen without added CRPwas not diminished in sera depleted
of PCh binding activity by passage through an anti-PCh-Sepharose column. Statistical analysis was undertaken by paired t test. B, the same experiment was
performed, but the increase in C3d deposition mediated by CRP was plotted against the amount of CRP bound to the plate under each condition. Ligands:
PCh-BSA (f), CPWS (●), or ES-62 (Œ). Small symbols represent data obtained for individual donor serum. Larger symbols represent data for pooled serum. C,
complement activation by ES-62 and other PCh ligands is through C1q. Normal serum or C1q-depleted pooled sera were used to determine C3d deposition
against ES-62, PCh-BSA, and CWPS. Data aremean S.E. of four replicates.D, CRP addition to serum increases complement C3bi deposition to ligand PCh-BSA
but not ES-62. Following incubation as in A at 37 °C for 30min, C3bi bound to the surface was detected with biotinylated anti-C3bi and streptavidin HRP. In A,
B, and D, the data are for between seven and nine different donors measured in three different experiments.
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rate-limiting for classical pathway activation. The likely expla-
nation for this effect was that the C4 was depleted (36). There-
fore, we addedES-62 to the sera and incubated at 37 °C to deter-
mine whether significant C4 was depleted. The assay for C4
relied on biotinylation of the thioester in only activeC4 remain-
ing after incubation. Indeed, the amounts of active C4 were
depleted by ES-62, and the amounts of C4 depleted (5–35%)
were approximately equivalent to the reduction seen in the
classical pathway activation assay (Fig. 9C). Predictably, addi-
tion of CRP to a concentration comparable with ES-62 lead to a
greater depletion (Fig. 9D).
Discussion
ES-62 derived from the rodent filarial nematode A. viteae
represents a readily available model protein for studying the
role of PCh on proteins derived from filarial nematode species
that parasitize humans. This is particularly the case because
PC-containing glycans, including chito-oligomers, and an iden-
tical PCh-glycan structure to that found on ES-62 have been
found in the human filarial nematode parasite O. volvulus (5).
The data in this report show that ES-62 binds strongly toCRP
in a PCh-dependent manner. The interaction of phosphodi-
ester-linked PCh has been shown to be about 10-fold weaker
than monoester PCh (14). However, the strong binding of
ES-62 forCRP reinforces previous data that suggest that a phos-
phodiester can be a strong ligand when linked to carbohydrate
(37). The binding of CRP to ES-62 is complex, as expected for
two multimeric proteins, and multiple different protein com-
plexes may be formed. However, a significant component has a
high avidity, as shown by surface plasmon resonance, which
gave a similar avidity in either orientation. Large complexes are
formedwhen purified proteins aremixed at equivalent concen-
trations in the presence of calcium. Complexes were also
formed in serum, as shown by the capture assays using C1q,
which demonstrated maximal binding at approximately equiv-
alent CRP-ES-62 concentrations. These assays also demon-
FIGURE 4. Demonstration of the CRPES-62C1q complex in serum. A, C1q binds to CRP/ES-62. ES-62 (Œ), PCh-BSA (f), or S. pneumoniae CWPS (●) were
immobilized on microtiter plates at concentrations that lead to equivalent CRP binding, determined by polyclonal anti-CRP binding. CRP (0.4 g/ml) was
added, followed by C1q at various concentrations (0, 0.2, 2.0, and 5.0 g/ml), and following washing, bound C1q was detected with anti-C1q-AP and
p-nitrophenyl phosphate substrate (optical density (OD) 415). B, CRPbinds to C1qonlywhen ligand is added to serum. Plateswere coatedwith C1q, and ligand
(, CWPS; , PCh-BSA;●, ES-62) was added to wells, with serum diluted 1 in 5 in VBSCaMg so that the final CRP concentration was 0.4 g/ml. Complex was
measured by CRP binding, determined using polyclonal anti-CRP -HRP. C, maximal CRP: ES-62 complex is captured to C1q at equal molarity of CRP and ES-62.
Plateswere coatedwith C1q, and serumwas diluted at 1:100 addedwith CRP at 0.03g/ml (‚), 0.06g/ml (E), and 0.125g/ml (). Various amounts of ES-62
were added, and CRP bound to the C1qwasmeasured using an anti-CRPmonoclonal antibody as in Fig. 1B.D, C1qwas recruited to CRP bound to ES-62. Plates
were coatedwith ES-62 and incubatedwith serumdiluted in VBSCaMgor VBSEDTA at 4 °C. The plateswerewashed, and boundproteinwas removed from the
surfacewith SDS sample buffer, run on a 12%SDS-PAGE gel, andWestern-blottedwith anti-C1q andCRP. Lanes 1 and 2, blotting for C1q (to reveal C1qA, C1qB,
and C1qC chains); lanes 3 and 4, blotting for CRP. Representative data from two to three donor sera are shown.
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strate an important point: that CRP and C1q do not interact
unless the CRP has bound ligand, implying that a conforma-
tional change is required in CRP to allow this binding. Models
of the binding of CRP to C1q imply that CRP may need to
undergo some conformation change, suggesting that the inter-
action is a strained one (20). In addition, the major protein in
human serum interacting with ES-62 was CRP. No binding of
ficolin 2 was seen, despite the observations that it bound PCh
attached to teichoic acid (38). It is possible that binding to
GlcNAc could be prevented by PCh substitution. We could see
little binding of IgM or IgG from serum of normal healthy
donors, but this may change in individuals with an induced
anti-PCh antibody response.
Our demonstration that, despite interactingwithCRP, ES-62
did not activate C3 was unexpected. We confirmed that there
was no difference between C4bp recruitment to C4b with the
different PCh-containing ligands under study. There have been
reports that high concentrations of CRP can interact with fac-
tor H (27), but here the concentrations were in the normal
range, and we saw no increase in factor H recruitment except
when associated with complement activation. In our study, all
CRP activity was entirely dependent on C1q, thus other
reported CRP activities, for instance through factor H-related 4
(34), were not involved. Therefore, ES-62 was capable of bind-
ing CRP and causing the change in CRP that is needed for bind-
ing of C1q, in turn leading to the rearrangement of C1q that
drives reorientation of its globular headgroup and the proposed
activation of C1r and, subsequently, C1s (39). That a flexible
ligand can do this also provides more evidence for a strained to
relaxed driving force for C1r/C1s activation (40).
The following question then arises: because we can observe a
strong activation and deposition of C4, why is there no C3
cleavage and thus noC3 convertase generated? PCh on ES-62 is
present on a highly flexible N-linked glycan. When the C4 is
cleaved and C4b binds to a region of ES-62 or CRP or a neigh-
boring attachment site, then the CRP-activated C1 complex is
still highly mobile and would likely move before it can cleave
C2.Variation in efficiency of generatingC3 convertase has been
observed before; for instance, lectin pathway activation ismuch
more efficient than the classical pathway (41, 42). The reason
for this is the relative off-rate of cleaved C4b. From mannose-
binding lectin (MBL)/MASP-2, the off-rate of C4b is relatively
slow, and because of the short half-life of the thioester of C4b,
thismeans that, when it attaches to a surface, it is closer than for
C4b generated by C1s with its faster off-rate, which can then
attach further from the C1s, which thenmakes C2 cleavage less
favorable. Normally, for the classical pathway, it requires four
C4b molecules to generate one convertase (43). The ES-62
CRPC1 complex containing the active C1s generates C4b,
which will attach to a local site, but the highly mobile nature of
the ligand will lead to movement of the C1s away from the site
where C4b attached, preventing interaction with C2 when it
binds to C4b. In this way the efficiency of generation of C3
convertase becomes very low.
FIGURE 5.ES-62-boundCRP leads toC4deposition.A, CRPbound to ES-62 leads to C4product deposition. Plateswere coatedwith ES-62 or other CRP ligand
at concentrations that bound similar amounts of CRP. Serum diluted in VBSCaMg from eight to ten normal healthy donors was added with or without CRP at
0.4 g/ml and incubated at 37 °C for 30 min. Deposited C4c was determined with biotinylated anti-C4c and streptavidin HRP. Statistical analysis was under-
taken by paired t test (n 9). B, bound CRP correlates with increased C4c deposition for all three ligands. Data were obtained as in A, but different serum and
CRP concentrations were used, and bound CRP was measured and plotted against the deposited C4c. PChBSA, f; ES-62,●; CWPS, Œ.
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This hypothesis was confirmed when we generated PCh
ligands that had different protein components and different
flexible components where the only similarity was the mobility
and the PCh. These behaved in the same way as ES-62 in terms
of complement activation.
An important conclusion from thiswork is that it emphasizes
the importance of the three-component stage when C4b
recruits C2, and then the C1 complex needs to cleave that C2 to
generate the C3 convertase as the rate-limiting step in the clas-
sical pathway. In devising the assay of C3 convertase generation
FIGURE 6. Lack of a role for complement regulatory factors. A, no significant difference between binding of C4 binding protein to immobilized ES-62-,
PChBSA-, or CWPS-coated microtiter plates. Plates were coated with ES-62, PCh-BSA, or CWPS as described previously and incubated with serum with (black
bars) or without CRP (gray bars). Following incubation for 30 min with serum diluted in VBSCaMg or VBSMgEGTA buffer with or without CRP (0.4 g/ml), the
plateswerewashed, and C4bpwas detectedwith biotinylated antiC4bp. Data are presented asmean S.E. of five different donor sera. B, factor H recruitment
to the plate surface following CRP-mediated complement activation in response to PCh-BSA and CWPS but not ES-62. PCh ligand was coated to the plate to
recruit equivalent CRP amounts, and following incubationwith serumwith or without added 0.4g/ml CRP at 37 °C for 30min, the amount of factor H bound
was determined. Two experiments on eight different donors were analyzed by paired t test.
FIGURE 7. ES-62 does not efficiently generate a C3 convertase. CRP addition to serum leads to active C2a generated in response to immobilized
PCh-BSA but poorly in response to immobilized ES-62. Plates were coated with ligand as described previously and incubated at 37 °C for 30 min, and
active C2a was detected with the biotinylated monoclonal antibody 175-62. Statistical analysis was undertaken by paired t test on 11 different sera in
two different experiments.
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using themonoclonal antibody to C2a, wewere able tomonitor
this stage of complement activation when alternative assays
involving Western blotting assays of C2 products were at best
hard to quantitate. This methodology will prove useful in the
examination of the efficiency of this stage of complement
activation.
Ligand-dependent CRP-mediated Complement Activation
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ES-62 is most likely to be found in solution in vivo, and this
would also restrict the chances of generating aC3 convertase by
the demonstrated depletion in C4 concentration. C4 is rate-
limiting, and not only does depletion reduce classical pathway
activation, but addition ofC4has been shown to increase it (36).
This may have relevance in evasion of the immune response by
filarial nematodes because it is known that these organisms are
capable of activating the complement system (44), and hence
theymay have evolved strategies to try andminimize this. It has
been observed, for example, that microfilaria larva stages of the
human parasite Loa loa acquire regulatory proteins from the
host to evade complement attack (45). The observed effects of
ES-62 could also help reduce unwanted pathology. In lymphatic
filarial infection, PCh-containing molecules have been shown
to be particularly detectable in patients with circulating micro-
filariae (larval forms) but without overt disease, inmost cases at
a serum concentration of about 0.1–1.0 g/ml (12). This con-
centration is similar to that of CRP in the normal serum range
and thus is able to make complex efficiently. It has also been
demonstrated in another study that this patient grouphas levels
of CRP that are not much above normal levels, whereas, in
people with overt pathology, CRP levels are greatly elevated
(46). The latter study also showed an inverse correlation
between serum levels of CRP and PCh-containing molecules.
This raises the possibility that a contributing factor to the
induction of pathology may be a low level of PCh-containing
molecules, resulting in a lack of early complement component
depletion via CRP.
The presence of PCh has been demonstrated in many non-
filarial helminth parasites (17), including Ascaris suum (47),
Hymenolepis diminuta (48), Toxocara canis (49, 50), and Echi-
nococcus granulosus (51), and in some cases it has been found to
be associatedwith glycans and/or to interact with CRP. In addi-
tion, the protozoan Leishmania donovani promastigotes
FIGURE 8.Highlymobile PCh ligands bind CRP but do not activate complement. A, CRP increases deposition of C3d onto PCh in PChBSA but not ES-62 or
the synthetic PCh ligands AGP-PCh and BSA-PEG4-PCh. Individual sera fromhealthy donorswith orwithout added CRP in VBSCaMgwere incubated at 37 °C in
ligand-coated plates in VBSCaMg, and C3d deposition was determined. Statistical analysis was undertaken by paired t test on 5–11 different sera in two
different experiments. B, the same experiment was performed, but the increase in C3d deposition mediated by CRP was plotted against the amount of CRP
bound to the plate under each condition when ligand concentration was varied. Ligands: PCh-BSA (●), ES-62 (Œ), AGP-PCh (), and BSA PEG4 PCh (f). C, PCh
of synthetic PCh-AGP is attached to N-linked carbohydrate. Shown is SDS-PAGE and Coomassie Blue (CB) staining (lanes 1–4) or immunoblot (lanes 5–8) with
anti-PCh (TEPC15) of AGP-PCh and an equivalent amount of PNGase-treated AGP-PCh. Lanes 1, 4, 5, and 8, 5g/ml; lanes 2, 3, 6, and 7, 2.5g/ml.WB, Western
blotting.D, CRP addition to serum increases C4c deposition onto AGP-PCh and BSA PEG4-PCh. Data for six different donor sera were analyzed by paired t test.
FIGURE 9.ES-62added to serumreduces classical complement activationand the rate-limiting factor activeC4.A, diagramof the effects of different PCh
forms on the complement pathway. B, classical complement activation was measured by C3d deposition onto IgM-coated microtiter plates. Serum diluted 1
to 100 in VBSCaMgwas either left untreatedor treatedwith ES-62 (0.1g/ml) for 30min at 37 °Cprior to addition to the IgM. Statistical analysiswas undertaken
by Wilcoxon matched pairs test (n 14 different sera in three different experiments). C, active C4 was measured following addition of ES-62 (0.5 g/ml) to
serum diluted 1 in 100 and incubation for 45min at 37 °C (n 6 different donor sera).D, as for B, but CRPwas added at 0.4g/ml final concentration. Data for
12 different donor sera in two separate experiments were analyzed by Wilcoxon matched pairs test.
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express flexible carbohydrate ligands (repeating phosphodi-
esters) for CRP (37, 52). However, whether the immune evasion
mechanism we describe for ES-62 in this manuscript applies to
these other organisms remains to be established. In addition,
some parasites, including strains of Trichomonas vaginalis,
express N-linked phosphorylethanolamine modifications (53),
and this raises the question whether SAP leads to a similar
incomplete complement activation.
Finally, also of note, complement has always been regarded
as a vital component of the innate response, but more recently
it has gained importance as a regulator of humoral and cellular
immunity through immune complex and/or C1q or ligation of
complement receptors (27, 54). The balance between effects on
T cells and antigen-presenting cells through activation prod-
ucts of complement such as C3a or complexes of C1q is consid-
ered an important determination of downstream immune
responses in antimicrobial activity and also autoimmunity (46).
The evasion strategy we describe is likely one of many that help
nematode survival through contributing to reduced comple-
ment activation and possibly associated consequences on
adaptive immunity. At the same time, it is interesting to spec-
ulate that the loss of such parasite manipulation of the host
could also contribute to the increase in chronic inflammatory
conditions, and this is often considered in relation to the “old
friends or hygiene hypothesis.” It is thus pertinent to consider
the therapeutic potential of a molecule with properties such as
ES-62 in these diseases. Certainly, given the leading role of CRP
in the general inflammatory response, a PCh-containing mole-
cule, which interferes with its activity, could have widespread
clinical application but particularly in medical emergencies
such as myocardial infarction and stroke, where prompt con-
trol of the inflammatory storm is mandatory. The use of a bis-
phosphocholine small molecule that complexes CRP was
shown to reduce inflammation and complement mediated
damage by depleting CRP (55). Future studies should thus now
extend to assessment of clearance of CRP and in vivo effects in
models of inflammatory disease. In addition, designing drug-
like analogues with similar effects to ES-62 may be a prudent
path to take.
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